Zürcher Kantonalbank Discloses Stake in Avadel Pharmaceuticals
Zürcher Kantonalbank (ZKB) has recently filed a form 8.3 disclosure with the Irish Takeover Panel, detailing its holdings in Avadel Pharmaceuticals plc. This disclosure, dated January 14, 2026, is required under the Irish Takeover Panel Act of 1997 for any interest in relevant securities exceeding 1%. The filing provides transparency regarding ZKB’s position and ensures compliance with regulatory requirements surrounding potential takeovers or meaningful ownership changes within Avadel Pharmaceuticals.
According to the disclosure, Zürcher Kantonalbank and its subsidiaries currently hold 37,707 ordinary shares of Avadel Pharmaceuticals, representing a 0.04% stake in the company’s relevant securities. This relatively small holding indicates a minor investment position by the bank. The report explicitly states that this disclosure does not encompass any cash-settled or stock-settled derivative transactions, nor does it pertain to the interests of other parties involved in any potential offer for Avadel Pharmaceuticals.
Notably, the Form 8.3 filing indicates no supplementary agreements, inducements, or understandings related to indemnity or options. this suggests a straightforward disclosure adhering to standard Rule 8.3 guidelines, without the need for additional documentation or a Supplemental Form 8. Investors and market observers frequently monitor these filings to gain insights into the ownership structure of companies and potential shifts in control.
Keywords: Avadel Pharmaceuticals, Zürcher Kantonalbank, form 8.3,Irish Takeover Panel,stock disclosure,investment,shareholder,regulatory filing,ZKB,AVDL.